SCHEMBL6317229

SCHEMBL6317229

C=CCNc1nc2c(nc1C(C)C(=O)O)c(=O)n(C)c(=O)n2C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 6/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
MAPK1 P28482 3/20 0.43
LMNA P02545 7/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
TSHR P16473 2/20 0.40
GALR3 O60755 1/20 0.40
RAB9A P51151 1/20 0.40
KDM4E B2RXH2 6/20 0.35
ALDH1A1 P00352 5/20 0.35
HPGD P15428 2/20 0.35
JAK2 O60674 1/20 0.35
PAX8 Q06710 1/20 0.35
GAA P10253 3/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
MAPT P10636 2/20 0.35
POLB P06746 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
CASP1 P29466 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6314078 0.83 KDM4E (0.36) HTTL3MBTL1MAPK1LMNASMN1; SMN2
SCHEMBL6322716 0.76 KDM4E (0.46) HTTL3MBTL1LMNATSHRRAB9A
SCHEMBL6315606 0.74 ALDH1A1 (0.56) HTTL3MBTL1MAPK1LMNAKDM4E
SCHEMBL6317109 0.73 ALDH1A1 (0.41) HTTL3MBTL1LMNAKDM4EALDH1A1
SCHEMBL6314318 0.69 ALDH1A1 (0.43) HTTL3MBTL1MAPK1LMNASMN1; SMN2
SCHEMBL28476188 0.67 KDM4E (0.44) HTTL3MBTL1LMNAKDM4EALDH1A1
SCHEMBL6323060 0.62 ALDH1A1 (0.42) HTTL3MBTL1MAPK1LMNAKDM4E
SCHEMBL6313853 0.62 LMNA (0.46) HTTL3MBTL1MAPK1LMNASMN1; SMN2
SCHEMBL6314837 0.61 ALDH1A1 (0.39) HTTL3MBTL1LMNATSHRKDM4E
SCHEMBL6396069 0.60 MAPT (0.40) HTTL3MBTL1MAPK1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6946465-B2 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2005-09-20 US claimed
US-20030236255-A1 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2003-12-25 US claimed
US-6946465-B2 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2005-09-20 US disclosed
US-20030236255-A1 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2003-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236255-A1 Immunosuppressive effects of pteridine derivatives TPMT, FKBP5, RRP15 HTT 1845/4885L3MBTL1 462/4885MAPK1 3557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.